Comparison of Clinical Efficacy Between Mepolizumab and Benralizumab in Severe Eosinophilic Asthma

A31. REAL WORLD ASTHMA TREATMENT OUTCOMES, BIOMARKER STUDIES, PHENOTYPING, AND SEVERITY ASSESSMENTS Pub Date : 2022-05-01 DOI:10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a1233

K. Okawa, T. Akamatsu, S. Sugiyama, K. Shiratori, H. Nakayasu, T. Masuda, S. Takahashi, Y. Kitahara, Y. Kishimoto, S. Sakurai, M. Saigusa, A. Yamamoto, S. Morita, K. Asada, T. Shirai

引用次数: 0

查看原文本刊更多论文

Mepolizumab与Benralizumab治疗重度嗜酸性哮喘的临床疗效比较

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

A31. REAL WORLD ASTHMA TREATMENT OUTCOMES, BIOMARKER STUDIES, PHENOTYPING, AND SEVERITY ASSESSMENTS

自引率

0.00%

发文量